We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
Read MoreHide Full Article
Editas Medicine, Inc. (EDIT - Free Report) announced that the FDA has cleared the initiation of the safety phase of its clinical study on investigational ex vivo gene-editing therapy EDIT-301 being developed for the treatment of sickle cell disease (“SCD”). The company is planning to initiate the phase I/II RUBY study to assess the safety and efficacy of EDIT-301 for the given indication.
SCD is caused by a mutation in the beta-globin gene that causes polymerization of the sickle hemoglobin protein (HbS).
Per the press release, Editas has identified a lead principal investigator and engaged a Clinical Research Organization. Meanwhile, before starting enrollment for the efficacy phase of the RUBY study, Editas will need to resolve a partial clinical hold by developing an improved potency assay and submiting the same to the FDA.
EDIT-301 is an experimental autologous cell therapy medicine under investigation for treating SCD. The FDA has already granted a Rare Pediatric Disease designation to EDIT-301. The candidate is being developed as a best-in-class one-time durable medicine for people suffering from SCD.
Shares of Editas were down 15.1% on Monday despite the encouraging news. However, the stock has skyrocketed 147% in the past year compared with the industry’s increase of 9.3%.
Editas currently has no approved product in its portfolio. Therefore, its pipeline development remains its key focus.
We note that EDIT-301 is Editas’ second pipeline candidate to enter clinical testing. The company’s lead candidate is EDIT-101, which employs CRISPR gene editing to treat LCA10 — a rare genetic illness that causes blindness. Editas completed dosing in the first cohort of the phase I/II BRILLIANCE study, which is evaluating EDIT-101 for LCA10.
LCA10 disease has a significant unmet need as no therapy is presently approved to cure the disease either in the United States or in the European Union.
Notably, apart from Editas, other companies are also using the CRISPR/Cas9 gene editing technology to develop their respective candidates for addressing various ailments. Intellia Therapeutics (NTLA - Free Report) and CRISPR Therapeutics (CRSP - Free Report) are among a few companies engaged in developing candidates to address different indications using CRISPR/Cas9 gene-editing technology.
Halozyme’s earnings estimates have been revised 3.6% upward for 2021 over the past 60 days. The stock has soared 127.8% in the past year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
Editas Medicine, Inc. (EDIT - Free Report) announced that the FDA has cleared the initiation of the safety phase of its clinical study on investigational ex vivo gene-editing therapy EDIT-301 being developed for the treatment of sickle cell disease (“SCD”). The company is planning to initiate the phase I/II RUBY study to assess the safety and efficacy of EDIT-301 for the given indication.
SCD is caused by a mutation in the beta-globin gene that causes polymerization of the sickle hemoglobin protein (HbS).
Per the press release, Editas has identified a lead principal investigator and engaged a Clinical Research Organization. Meanwhile, before starting enrollment for the efficacy phase of the RUBY study, Editas will need to resolve a partial clinical hold by developing an improved potency assay and submiting the same to the FDA.
EDIT-301 is an experimental autologous cell therapy medicine under investigation for treating SCD. The FDA has already granted a Rare Pediatric Disease designation to EDIT-301. The candidate is being developed as a best-in-class one-time durable medicine for people suffering from SCD.
Shares of Editas were down 15.1% on Monday despite the encouraging news. However, the stock has skyrocketed 147% in the past year compared with the industry’s increase of 9.3%.
Editas currently has no approved product in its portfolio. Therefore, its pipeline development remains its key focus.
We note that EDIT-301 is Editas’ second pipeline candidate to enter clinical testing. The company’s lead candidate is EDIT-101, which employs CRISPR gene editing to treat LCA10 — a rare genetic illness that causes blindness. Editas completed dosing in the first cohort of the phase I/II BRILLIANCE study, which is evaluating EDIT-101 for LCA10.
LCA10 disease has a significant unmet need as no therapy is presently approved to cure the disease either in the United States or in the European Union.
Notably, apart from Editas, other companies are also using the CRISPR/Cas9 gene editing technology to develop their respective candidates for addressing various ailments. Intellia Therapeutics (NTLA - Free Report) and CRISPR Therapeutics (CRSP - Free Report) are among a few companies engaged in developing candidates to address different indications using CRISPR/Cas9 gene-editing technology.
Zacks Rank & Stock to Consider
Editas currently carries a Zacks Rank #4 (Sell).
A top-ranked stock in the biotech sector is Halozyme Therapeutics, Inc. (HALO - Free Report) , which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Halozyme’s earnings estimates have been revised 3.6% upward for 2021 over the past 60 days. The stock has soared 127.8% in the past year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>